177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

• Main Authors: Majid Assadi, Hojjat Ahmadzadehfar
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2019-01-01
• Series: World Journal of Nuclear Medicine
• Subjects: 177lu; dotatate; prostate-specific membrane antigen; radioiodine-refractory differentiated thyroid cancer
• Online Access: http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=4;spage=406;epage=408;aulast=Assadi

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with177Lu-DOTATATE and177Lu-PSMA, presumably as a first report in this regard.